Related Experiment Videos
Deep vein thrombosis resolution is not accelerated with increased neovascularization
Manu R Varma1, Daria M Moaveni, Nicholas A Dewyer
1Department of Surgery, University of Michigan Medical School, Ann Arbor, USA.
Journal of Vascular Surgery
|September 1, 2004
Summary
Promoting neovascularization in deep venous thrombosis (DVT) models with angiogenic factors increased blood vessel growth. However, this did not lead to smaller or less fibrotic clots, suggesting other mechanisms are key for DVT resolution.
Area of Science:
- Vascular Biology
- Thrombosis Research
- Regenerative Medicine
Background:
- Deep venous thrombosis (DVT) resolution involves complex processes including fibrinolysis, neovascularization, and fibrosis.
- Current therapeutic strategies aim to accelerate DVT resolution and minimize anticoagulation-related bleeding risks.
Purpose of the Study:
- To investigate whether promoting neovascularization within deep venous thrombosis (DVT) can accelerate clot resolution.
- To evaluate the effects of specific pro-angiogenic factors on DVT neovascularization and overall clot burden.
Main Methods:
- A rat model of stasis deep venous thrombosis (DVT) was established.
- Pro-angiogenic factors (bFGF, ENA-78) or an angiostatic factor (IP-10) were administered locally and systemically.
- Thrombus neovascularization, weight, collagen content, and blood flow were assessed at 4 and 8 days post-DVT induction.
Main Results:
- Administration of bFGF and ENA-78 significantly increased thrombus neovascularization at 8 days compared to controls.
- Increased neovascularization did not correlate with reduced thrombus weight or collagen content.
- Only bFGF treatment significantly improved post-thrombotic blood flow, while ENA-78 increased intrathrombus bFGF levels.
Conclusions:
- While pro-angiogenic compounds can enhance DVT neovascularization, this effect does not directly translate to accelerated clot dissolution or reduced fibrosis.
- Mechanisms beyond neovascularization may play a more critical role in hastening DVT resolution.
- Targeting solely neovascularization may not be sufficient for developing improved DVT therapies.